MedPath

Predictors of Response to Iron and Erythropoietin Stimulating Agents

Phase 4
Completed
Conditions
Renal Failure Chronic
Anemia
Interventions
Registration Number
NCT03658876
Lead Sponsor
Imperial College London
Brief Summary

The purpose of the study is to identify predictors of treatment response. This involves collected baseline clinical parameters and bloods for biochemical parameters prior to administering the study treatment. A positive outcome following treatment was defined as an uptitration of haemoglobin by greater than 5g/l within 2 months. The study evaluated the participants response to treatment against the clinical and biochemical information collected prior to treatment being received.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
197
Inclusion Criteria
  • All prevalent haemodialysis patients, established for greater than 3 months
Read More
Exclusion Criteria

Inability to consent Bone marrow disorder Transfusion dependence Active bleeding Active infection Active malignancy Frail with either frequent hospital admissions or unable to follow trial protocol due to differing target haemoglobin

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Iron groupIron Sucrose Solution for Injection-
EPO groupEpoetin Beta-
Primary Outcome Measures
NameTimeMethod
Hemoglobin IncrementationWithin 2 months

Incrementation of haemoglobin of 5g/l following treatment

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath